secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001193125-24-070333
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem receives non-binding term sheet to acquire biotech Tango for $20M in stock
--------------------------------------------------------------------------------

- RA Capital owns ~47.5% of Eliem and majority of Tango; special committee oversees strategic review.
- Eliem valued at $110M, Tango at $20M; post-deal Tango holders get 15.4% of combined entity.
- Concurrent PIPE financing to be sized by parties; RA Capital expected to participate.
- Deal requires approval of majority of Eliem shares not held by RA Capital (non-waivable condition).
- Non-binding; subject to due diligence, definitive agreement, and independent committee clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524070333/0001193125-24-070333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524070333/d784366d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-070333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer